Deep Medicine Acquisition (Deep Medicine Acquisition) Operating Income : $-1.91 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Deep Medicine Acquisition Operating Income?

Deep Medicine Acquisition's Operating Income for the three months ended in Sep. 2023 was $-0.36 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.91 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Deep Medicine Acquisition's Operating Income for the three months ended in Sep. 2023 was $-0.36 Mil. Deep Medicine Acquisition's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Deep Medicine Acquisition's Operating Margin % for the quarter that ended in Sep. 2023 was %.

Deep Medicine Acquisition's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Deep Medicine Acquisition's annualized ROC % for the quarter that ended in Sep. 2023 was -21.28%. Deep Medicine Acquisition's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -21.28%.

Deep Medicine Acquisition Operating Income Historical Data

The historical data trend for Deep Medicine Acquisition's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deep Medicine Acquisition Operating Income Chart

Deep Medicine Acquisition Annual Data

Trend

Mar21

Mar22

Mar23

Operating Income

-0.41

-2.17

Deep Medicine Acquisition Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Operating Income	Get a 7-Day Free Trial							-0.72	-0.42	-0.76	-0.37	-0.36

Deep Medicine Acquisition Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.91 Mil.

Deep Medicine Acquisition (NAS:DMAQ) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Deep Medicine Acquisition's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-1.444 * ( 1 - 0% )	/	( (8.243	+	5.328)	/ 2 )
=	-1.444	/	6.7855
=	-21.28 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.013	-	1.228	-	( 0.542	-	max(0, 3.293	-	10.013	+	0.542	))
=	8.243

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7.005	-	1.32	-	( 0.357	-	max(0, 3.47	-	7.005	+	0.357	))
=	5.328

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Deep Medicine Acquisition's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.444	/	( ( (0 + max(8.243, 0))	+	(0 + max(5.328, 0)) )	/	2 )
=	-1.444	/	( ( 8.243	+	5.328 )	/	2 )
=	-1.444	/	6.7855
=	-21.28 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	9.471)	-	(1.228	+	0	+	0)
=	8.243

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	6.648)	-	(1.32	+	0	+	4.4408920985006E-16)
=	5.328

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Deep Medicine Acquisition's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-0.361	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Deep Medicine Acquisition Operating Income Related Terms

Thank you for viewing the detailed overview of Deep Medicine Acquisition's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Deep Medicine Acquisition (Deep Medicine Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Deep Medicine Acquisition Corp (NAS:DMAQ) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Madison Avenue, 12th Floor, New York, NY, USA, 10017

Website

Deep Medicine Acquisition Corp is a blank check company.

Executives

John Chiang	director	3538 TORRANCE BLVD., UNIT 177, TORRANCE CA 90503
Bryant Fong	director	2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Humphrey P Polanen	director, officer: Chief Executive Officer	C/O HERITAGE COMMERCE CORP, 150 ALMADEN BLVD, SAN JOSE CA 95113
Weixuan Luo	officer: Chief Financial Officer	40 WALL STREET, 29TH FLOOR, NEW YORK NY 10005
Marc Hamer	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Bright Vision Sponsor Llc	10 percent owner	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Ronald M. Razmi	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Hongliang Ren	director	7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Wanlei Miao	director	595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017
Tina Spires	director	595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017